Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy An advisory statement from the American Dental Association Council on Scientific Affairs
Updated recommendations for managing the care of patients receiving oral bisphosphonate therapy An advisory statement from the American Dental Association Council on Scientific Affairs
复制标题
DOI：
10.14219/jada.archive.2008.0110
复制
发表时间：
2008-12-01
影响因子：
3.9
通讯作者：
Migliorati, Cesar A.
中科院分区：
文献类型：
--
作者：
Edwards, Beatrice J.;Hellstein, John W.;Migliorati, Cesar A.
背景和概述。2005年，美国牙科协会（ADA）科学事务委员会召集了一个专家小组，为牙医治疗接受口服双膦酸盐治疗的患者制定临床建议。《美国牙科协会杂志》在2006年发表了结果报告。2008年的建议声明是2006年临床建议定期更新的第一份。根据对现有文献的回顾，2008年的咨询声明得出结论，对于接受双膦酸盐治疗的患者，发生双膦酸盐相关的颌骨骨坏死（BON）的风险显然仍然很低。它还得出结论，目前的筛查和诊断测试在预测患者患病风险方面是不可靠的。本声明更新了2006年关于普通牙科、牙周病管理、种植体放置和维护、口腔颌面外科、牙髓学、修复性牙科和口腔修复学以及正畸学的建议。
Background and Overview. In 2005, the American Dental Association (ADA) Council on Scientific Affairs convened an expert panel to develop clinical recommendations for dentists treating patients who are receiving oral bisphosphonate therapy. The Journal of the American Dental Association published the resulting report in 2006. This 2008 advisory statement is the first of projected periodic updates of the 2006 clinical recommendations.Conclusion. This 2008 advisory statement concludes, on the basis of a review of the current literature, that for patients receiving bisphosphonate therapy, the risk of developing bisphosphonate-associated osteonecrosis (BON) of the jaw apparently remains low. It also newly concludes that current screening and diagnostic tests are unreliable for predicting a patient's risk of developing the condition. This statement updates the 2006 recommendations regarding general dentistry, management of periodontal diseases, implant placement and maintenance, oral and maxillofacial surgery, endodontics, restorative dentistry and prosthodontics, and orthodontics.